MB-106
Mustang Bio
['lymphoma', 'follicular']
#17icml: data from the follicular #lymphoma cohort of the ongoing phase 1/2 clinical trial of mb-106 demonstrate treatment with the cd20-targeted, autologous car t-cell therapy resulted in high orr and cr rate and car t persistence. $mbio 
Mustang Bio, a Fortress Biotech company, is focused on the development of novel immunotherapies and gene therapies in areas of unmet need.